RxDoctor Payments Data

Robert Killian, MD

Adult Medicine · Seattle, WANPI 1578553053

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,690 of the $11,862 with a category attached, or 64.8%. 5 manufacturers reported payments, led by Viiv Healthcare Company at 44.4% of the total. Reporting peaked in 2023 at $4,935 and has fallen 91.4% since, to $423 in 2025.

$11,862in general payments, 2019–2025

Across 95 payments — averaging $124.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$5K
  • Gilead$5K
  • Senseonics, Incorporated$1K
  • Novo Nordisk$47
  • Hologic Sales And Service, LLC$42

What the payments were for

  • Consulting fees$7,69065%
  • Speaking & faculty fees$1,44012%
  • Travel & lodging$8467%
  • Food & beverage$1,88616%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult medicine providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$12,923
Medicare patients
35
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala76$351,931
DovatoDolutegravir Sodium/Lamivudine27$79,069
DescovyEmtricitabine/Tenofov Alafenam12$30,698
OzempicSemaglutide18$16,341
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)13$5,468
Methadone Hcl13$1,118
Testosterone Cypionate17$1,069
Gabapentin18$475
Amlodipine Besylate45$439
Atorvastatin Calcium28$381
Losartan Potassium22$350
Rosuvastatin Calcium22$322
Lisinopril22$320
Pravastatin Sodium18$269
Levothyroxine Sodium21$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$5,062$382,63088 claims
Viiv Healthcare CompanyDovato$5,272$79,06927 claims
Novo NordiskOzempic$47$16,34118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Washingtonon file to place this against a meaningful peer group, so we don't.

Other adult medicine in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →